comparative effectiveness

Research in Review

Clinical Pathway Improves Adherence to Guideline-Concordant Pneumonia Care

07/29/2016

JCP Editors

A clinical pathway along with monthly feedback may help to improve adherence to guideline-concordant care for patients with community-acquired pneumonia (CAP), according to a study published in Plos One. CAP is a...

A...

07/29/2016

Journal of Clinical Pathways

Research in Review

Vemurafenib Improves Response in Patients With Thyroid Cancer

07/28/2016

JCP Editors

Vemurafenib, a drug originally approved for use in patients with BRAF-positive melanoma, has also shown promising anti-tumor activity in some patients harboring this same mutation in thyroid cancer, according to the...

...

07/28/2016

Journal of Clinical Pathways

Research in Review

Radiotherapy Timing Affects Outcomes for Small-Cell Lung Cancer

07/23/2016

JCP Editors

Earlier or shorter delivery of thoracic radiotherapy in addition to planned chemotherapy my significantly improve 5-year overall survival, albeit with more acute toxicity, according to a study published in the Annals...

...

07/23/2016

Journal of Clinical Pathways

Research in Review

Adjuvant Chemotherapy Improves Colon Cancer Outcomes

07/22/2016

JCP Editors

Adjuvant chemotherapy may improve survival in patients with stage II colon cancer regardless of treatment regimen, patient age, or high-risk pathologic features, according to a study published in the journal Cancer....

...

07/22/2016

Journal of Clinical Pathways

Research in Review

Little Difference Between MSUS and DAS28-driven Treatment Strategies for Rheumatoid Arthritis

07/18/2016

JCP Editors

In early rheumatoid arthritis (RA), musculoskeletal ultrasound (MSUS)-driven treat-to-target strategies may led to more intensive treatment than disease activity score in 28 joints (DAS28)-driven strategies, but not...

In...

07/18/2016

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Two NSCLC Treatments Compared

07/15/2016

JCP Editors

Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...

...

07/15/2016

Journal of Clinical Pathways

Research in Review

Two Studies Support Immunotherapeutic Agent As First-Line Treatment for NSCLC

07/07/2016

JCP Editors

Nivolumab has demonstrated encouraging activity and acceptable tolerability as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC), according to the results of two phase I,...

...

07/07/2016

Journal of Clinical Pathways

Department

Peri-operative Chemo and Radiotherapy Equally Effective for Gastric Cancer

07/06/2016

JCP Editors

Post-operative chemotherapy may be just as effective as chemoradiotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the European...

...

07/06/2016

Journal of Clinical Pathways

Research in Review

Cisplatin and Paclitaxel Most Cost-Effective Chemotherapy Combination for Cervical Cancer

06/28/2016

JCP Editors

Cisplatin and paclitaxel may be the most cost-effective chemotherapy combination for women with advanced, persistent, or recurrent cervical cancer, according to research published in Dovepress. In the study,...

...

06/28/2016

Journal of Clinical Pathways

Research in Review

Variation in Regimen Cost-Effectiveness for Metastatic Colon Cancer

06/24/2016

JCP Editors

A study published in the Journal of Managed Care & Specialty Pharmacy has shown that outcomes for metastatic colon cancer and the cost of care can both vary significantly based on which therapies are used in...

A...

06/24/2016

Journal of Clinical Pathways